GLP-1 agonists are not a replacement for antihypertensive therapy but may complement it
You may be a good candidate for this treatment if you meet any of the following conditions: You cannot meet your weight loss goals through diet and exercise alone Youre at risk of cardiovascular disease Youre overweight or have obesity You have type 2 diabetes While there are many benefits to Semaglutide, this treatment is not right for everyone
Boehringer Ingelheim International GmbH Key Target Audience Market Players Investors End-users Government Authorities Consulting And Research Firm Venture capitalists Value-Added Resellers (VARs) Recent Development In March 2023, the NHS approved Wegovy, a weight reduction injectable that mimics the hormone glucagon-like peptide-1 (GLP-1) and inhibits hunger
Currently, the efficacy estimand for injectable semaglutide demonstrates greater weight loss compared to the available oral tablet
However, researchers are interested in its application in other areas of the bodyparticularly in regards to wound healing, neuroprotection, and muscle and tissue growth
